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ABSTRACT:
Wnt signalling is an important component of vertebrate development, required 
for specification of the neural crest. Ten Wnt receptors [Frizzled receptor 1-10 
(Fzd1-10)]  have  been  identified  so  far,  some  of  which  are  expressed  in  the 
developing nervous system and the neural crest. Here we show that expression 
of one such receptors, Fzd6, predicts poor survival in neuroblastoma patients 
and marks rare, HIF1/2 α-positive cells in tumour hypoxic areas. Fzd6 positive 
neuroblastoma  cells  form  neurospheres  with  high  efficiency,  are  resistant  to 
doxorubicin killing and express high levels of mesenchymal markers such as Twist1 
and Notch1. Expression of Fzd6 is required for the expression of genes of the non-
canonical Wnt pathway and the spheres forming activity. When transplanted into 
immunodeficient mice, neuroblastoma cells expressing the Fzd6 marker grow more 
aggressively than their Fzd6 negative counterparts. We conclude that Fzd6 is a 
new surface marker of aggressive neuroblastoma cells with stem cell-like features. 
INTRODUCTION
Neuroblastoma, the most common extracranial solid 
tumor in infancy, is an embryonic cancer originating 
from the neural crest [1]. The tumor develops in the 
sympathetic nervous system, typically the adrenal medulla 
or paraspinal ganglia, and is characterised by a wide 
spectrum of clinical behaviour.  Localised neuroblastoma 
is curable, while metastatic neuroblastoma has a poor 
prognosis and high rate of relapse after chemotherapeutic 
treatments [1]. 
The neural crest is a multipotent cell population 
localized at the edge between the neural plate and non-
neural ectoderm (epidermis). Neural crest cells migrate 
throughout the embryo and differentiate into several cell 
types, including neurons, chondroblasts and melanocytes. 
Molecular signals controlling neural crest specification 
are not fully understood but Wnt proteins, bone 
morphogenetic proteins (BMPs) and Fibroblast Growth 
Factors (FGFs) have all been associated with neural crest 
induction [2].
Wnt signaling is important in pattern specification, 
migration of the neural crest and is distinguished in 
canonical and non-canonical pathways. In the canonical 
pathway, binding of Wnt ligands to Frizzled receptors 
induces  the  translocation  of  β-catenin  in  the  nucleus, 
where it engages the N-terminus of Tcf/Lef transcription 
factors. In absence of Wnt signal, Tcf/Lef proteins repress 
target genes whilst the interaction with β-catenin converts 
them into transcriptional activators [3-5]. Non-canonical 
pathways are the planar cell polarity (PCP) and calcium 
mobilisation via activation of G proteins. PCP plays an 
important role in directional migration of neural crest cells 
during development, suggesting that non-canonical Wnt 
signalling is a key element of this process [6]. The seven 
trans-membrane protein frizzled (Fzd) transduce the Wnt Oncotarget 2011; 2:  976 - 983 977 www.impactjournals.com/oncotarget
signal and 10 receptors have been so far identified, some of 
which have been shown to be involved in the development 
of the nervous system and stem cell signalling [7-12]. 
In this study, we investigated whether surface 
expression of frizzled receptors could be of clinical and 
biological relevance in neuroblastoma. 
RESULTS AND DISCUSSION
We initially investigated whether frizzled receptors 
were associated with survival of neuroblastoma patients. 
Using the neuroblastoma prognosis databases on the 
Oncogenomics repository, we found that only Fzd6, among 
the  10  frizzled  receptors,  was  statistically  significantly 
associated with poor survival in all databases (figure 1A 
and http://home.ccr.cancer.gov/oncology/oncogenomics). 
Notably, immunofluorescence analysis of tissue sections 
from primary human neuroblastomas showed that Fzd6 
positive cells were rare (1-8 per one thousand cells, Suppl. 
Table 1; Fig. 1B, panel 1). All of these cells expressed 
HIF1α that was not detected in Fzd6 negative cells (Fig. 
1B, panel 2). In addition, all Fzd6 positive cells showed 
prominent  nuclear  staining  for  HIF2α,  indicative  of 
transcriptionally active status. HIF2α was also detected in 
60±2 % Fzd6 negative cells, although with a cytoplasmic 
staining pattern (Fig. 1B, panel 3). These findings suggest 
that Fzd6 positive cells localise in tumour hypoxic areas 
[13]. We next assessed whether established or primary 
mouse and human neuroblastoma cell lines were positive 
to Fzd6. The latter cells were freshly disaggregated from 
a metastasis of a stage 4 neuroblastoma patient and short-
term cultured. Only a small percentage of cells within the 
population of each cell line were stained with the Fzd6 
antibody, further corroborating the hypothesis that Fzd6 
marks a specific cell subset within the bulk of the tumour 
(Fig. 2).
To investigate whether the expression of Fzd6 
could be compatible with a stem cell-like phenotype, we 
FACS-sorted Fzd6 positive and negative cells from the 
neuroblastoma cell line R6-2, recently established by 
our group from MYCN mice [14], since these cells were 
enriched in Fzd6 positive cells compared to others (Fig. 
2). Firstly, we observed that Fzd6-positive neuroblastoma 
cells formed more neurospheres in serum free medium 
and were more invasive than their Fzd6-negative 
counterparts in in vitro  invasion  assays  (Fig.  3  A,B). 
To  extend  these  findings,  we  investigated  whether  the 
positive and negative populations also differed in terms 
of gene expression. Fzd6 positive, compared to negative, 
cells presented activation of canonical and non-canonical 
Wnt target genes such as MYC, CD44, cyclin D1, Twist1, 
tyrosine hydroxylase (TH), and the neural stem cell marker 
Notch1. In contrast, expression of other non-Wnt target 
genes and stem cells markers Oct4, Sox1, Sox2 and DHH 
was either undetected or unchanged (Fig. 3C). A feature 
of neuroblastoma cancer stem cells is their ability to resist 
drug killing [15]. Fzd6 positive cells were significantly 
more resistant to doxorubicin killing than their negative 
counterparts (Fig. 3D). These experiments supported the 
hypothesis that Fzd6 positive cells, at least according to 
these in vitro assays, have a phenotype reminiscent of 
cancer stem cells. 
Frizzled receptors can activate canonical or non-
Figure 1: Fzd6 is associated with poor prognosis in 
neuroblastoma and marks cells with features of cancer 
stem cells. A) Kaplan Meier survival estimation curves were 
generated using the Oncogenomics website (http://home.ccr.
cancer.gov/oncology/oncogenomics). The grey line between 
high and low curves indicates median values.  P values from 
log rank analysis are indicated at the bottom of each panel. 
B). Panel 1. Immunofluorescence analysis of Fzd6 expression 
in a representative metastatic primary human neuroblastoma. 
Green=Fzd6; Blue=DAPI. Panel 2. Immunofluorescence analysis 
to show co-localisation of Fzd6 and nuclear HIF1α. Green=Fzd6; 
red=HIF1α; blue=DAPI. Panel 3. Immunofluorescence analysis 
to show co-localisation of Fzd6 and nuclear HIF2α.  A few Fzd6 
negative cells show cytoplasmic HIF2α staining. Green=Fzd6; 
red=HIF2α; blue=DAPI.
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canonical Wnt pathways. To distinguish between the 
two  possibilities,  we  stained  FACS  sorted  R6-2  cells 
with an antibody reactive against activated beta-catenin 
or phosphorylated JNK as a read out for activation of 
the canonical and non-canonical pathways, respectively. 
Fzd6 positive cells showed a slight enrichment of 
activated catenin compared to negative cells; however 
the difference was not statistically significant (Fig. 4A). 
Notably, phosphorylated JNK was strongly increased in 
Fzd6 positive, compared to negative, cells, indicating 
activation of the non-canonical pathway (Fig. 4B). In 
agreement with this observation, Wnt4/Fzd6 signalling 
Figure 2: Expression of Fzd6 in primary or established neuroblastoma cell lines. Cells were stained with FITC labelled Fzd6 
antibodies and subjected to flow cytometry analysis to enumerate cells positive or negative to the marker. An isotype matched, irrelevant 
fluorescinated antibody was used as a negative control.  
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was recently shown to activate the non-canonical 
pathway in murine haematopoietic precursor cells [16]. 
Fzd6 signalling is required for the stem-like phenotype 
of neuroblastoma cells, since neurospheres formation 
was drastically reduced in cells transfected with an Fzd6 
siRNA  (Fig.  5A).  The  non-canonical  Wnt-target  genes 
CD44 and TH, along with the mesenchymal transcription 
factor Twist1, were downregulated, whereas expression of 
the canonical Wnt-target genes MYC and cyclin D1 was 
unchanged in Fzd6 interfered cells, further corroborating 
the hypothesis that Fzd6 is mainly required to activate 
the Wnt non-canonical pathway in neuroblastoma cells 
(Fig. 5B). The requirement for the expression of Fzd6 for 
neurospheres formation was validated using an additional 
Fzd6 siRNA (supplementary figure 1). 
To gain insights on the role of the Fzd6 receptor in 
the context of a physiologically relevant human model, we 
used primary neuroblastoma cells freshly disaggregated 
from a metastasis of a stage 4 neuroblastoma patient. 
Fzd6 positive and negative cells were separated by FACS 
sorting of short-term cultures and injected orthotopically 
into the adrenal glands of immunodeficient mice. After 
7  weeks,  we  observed  significantly  larger  tumors  in 
the adrenal glands of mice injected with Fzd6 positive 
cells, compared to those formed by Fzd6 negative cells. 
Furthermore,  after  8.5  weeks  there  were  significantly 
more Fzd6 positive, than negative, cells metastasising 
to the bone marrow of tumor injected mice (Fig. 6A). 
Expression of Notch1, the proliferation marker ki67 and 
the Wnt target gene and mesenchymal stem cell marker 
Twist1  were  significantly  increased  in  Fzd6  positive 
tumors, corroborating the hypothesis that Fzd6 marks 
Figure 3: Fzd6 expressing cells display biological features of cancer stem cells.  A) Neurospheres assay. The number of 
spheres per well was plotted against the number of cells plated. Error bars indicate standard deviations, statistical significance was assessed 
using two-sided Student-T test (n=3). The phenotype of spheres deriving from Fzd6+ and Fzd6- cells is shown in the inset. B) In vitro 
invasion assay. Error bars indicate standard deviations, statistical significance was assessed using two-sided Student-T test (n=3). C) Gene 
expression analisis of Fzd6 positive and negative R6-2 neuroblastoma cells. Gene expression levels in Fzd6 negative cells were arbitrarily 
set to 1. CcND1 indicates cyclin D1. Error bars indicate standard deviations of triplicate wells. The experiment was repeated twice with 
similar results. D) Cell death assay. Mouse neuroblastoma cells were sorted as and plated in the presence or absence of the indicated 
concentrations of doxorubicin (doxo) for 24 or 48 hours. Cell death was scored by trypan blue dye exclusion assay. Error bars indicate 
standard deviations, statistical significance was assessed using two-sided Student-T test (n=3).Oncotarget 2011; 2:  976 - 983 980 www.impactjournals.com/oncotarget
cells with enhanced capacity to proliferate and metastasise 
in vivo  (Fig.  6B;  quantification  of  this  experiment  is 
shown  in  supplementary  figure  2).  Expression  of  the 
vascular  marker  α-SMA  was  significantly  increased  in 
Fzd6 positive, compared to negative, tumours, suggesting 
that Fzd6 expression is associated to a vascular phenotype 
(Fig. 6B and supplementary figure 2). Interestingly, one 
feature of neuroblastoma stem cells is their ability to 
directly and indirectly promote vasculogenesis [17].  
In further experiments, the classical neuroblastoma 
cell  line  SHSY5Y  was  FACS  sorted  after  staining 
with the Fzd6 antibody and injected into the flanks of 
immunodeficient SCID mice. Cells positive for the Fzd6 
marker formed statistically significantly larger tumours 
than the Fzd6 negative counterparts,  (Fig. 6C). Assessment 
of gene expression before injections into mice confirmed 
that Wnt-target genes and Notch1 were activated in Fzd6 
positive, compared to negative, SHSY5Y cells (Fig. 6D).
A previous study showed that Fzd6 expression is 
up-regulated in Chronic Lymphocytic Leukemia (CLL), 
marking a population of leukaemic stem cells, and 
development  of  CLL  is  delayed  significantly  in  Fzd6 
knock out mice [12]. Moreover, Fzd6 is highly expressed 
in the slow-dividing fraction of human cordon blood 
progenitor cells, suggesting a role in self-renewal [18]. 
In this study, we have shown that Fzd6 expression is 
associated with poor prognosis of neuroblastoma patients, 
marking tumour cells that grow aggressively in vivo. Fzd6 
positive neuroblastoma cells reside in hypoxic areas and 
express nuclear HIF2α, which was shown to mark tumour 
initiating cells in neuroblastomas [19]. Fzd6 positive cells 
display biological features that have been detected in 
cancer stem cells, such as the ability to form neurospheres 
with  high  efficiency,  increased  invasive  ability  and 
resistance to chemotherapeutic drugs. Furthermore, cells 
positive to Fzd6 express stem cell associated genes. 
Whether Fzd6 is a genuine marker of neuroblastoma 
stem cells will need to be further assessed in serial 
transplantation experiments in which Fzd6 positive cells 
isolated from neuroblastoma biopsies will be injected into 
immunodeficient mice to recapitulate patients’ tumours. 
The stem cell markers CD133, CD24 and CD34 have 
been detected on the surface of neuroblastoma cells [20, 
21] but none of these molecules is specific to the neural 
crest and their expression is detected in normal neural and 
haematopoietic stem cells. Therefore, these markers are 
unlikely to be used as therapeutic targets in neuroblastoma 
or other forms of cancer. Fzd6 expression is mainly 
restricted to embryonic life, suggesting that Fzd6 could be 
pharmacologically targeted in cancer patients to eliminate 
aggressive cell subsets within the bulk of tumours. 
Therapeutic approaches aimed at inhibiting Fzd6 positive 
tumor cells, if developed, could hold promise in the clinic 
for the treatment of aggressive forms of neuroblastoma 
and other tumour types showing expression of this marker.  
MATERIALS AND METHODS
Neurospheres assay
R6-2 neuroblastoma cells from MYCN transgenic 
mice [14] were incubated with a Fzd6 antibody and a 
fluorescinated  secondary  antibody  (both  from  R&D 
Systems, Minneapolis, MN). Cells were separated 
by  FACS  sorting  and  cultured  in  serum  free  medium 
consisting of a 3:1 mixture of DMEM:F12, (Invitrogen), 
containing 2% B27 supplement (Gibco), 40 ng/ml basic 
fibroblast  growth  factor  2  (bFGF)  (Millipore)  and  20 
ng/ml epidermal growth factor (Invitrogen). Cells were 
seeded into microwell plates at a concentration ranging 
from 500 to 1 cell per well, and maintained in culture for 
7 days.
Western blot
Cells were lysate in RIPA Buffer (10 mM Tris-Cl 
[pH 8.0], 1 mM EDTA, 1% Triton X-100, 0.1% sodium 
A
B
Figure 4: Fzd6 expression is associated to activation 
of the non-canonical Wnt pathway. A) Fzd6 positive and 
negative cells were subjected to immunofluorescence staining 
with an antibody specific for activated beta-catenin (indicated 
by ABC). The average of the percentages of cells positive for 
the antibody in multiple fields are plotted in the y axis. The 
error bars indicate standard deviations. The difference is not 
statistically significant (p=0.1). B) western blot analysis showing 
the expression of total (left panel) and activated/phospho (right 
panel) JNK in Fzd6 positive (+) and negative (-) neuroblastoma 
cells. Oncotarget 2011; 2:  976 - 983 981 www.impactjournals.com/oncotarget
deoxycholate, 0.1% SDS, 140 mM NaCl), protease and 
phosphatase inhibitors (Roche). Proteins were separated by 
SDS/PAGE on 10% gels, transferred to PVDF membrane 
(Amersham, Pharmacia), and incubated with antibodies 
against SAPK/JNK (Cell Signalling) or Phospho-SAPK/
JNK  (Thr183/Tyr185)  (Cell  Signaling).  Immunoblots 
were visualised using the enhanced chemoluminescence. 
Immunofluorescence analysis of active-β-catenin
Cells  were  fixed  in  4%  paraformaldehyde  and 
permeabilized in 0.5% TRITON-X in PBS. Blocking was 
carried out with 50% Normal Goat Serum (NGS) and 1% 
BSA in PBS. Cells were next incubated for 1 hour with 
1:1000 dilution in blocking buffer of anti-active-β-catenin 
(anti-ABC, clone 8E7, Millipore). After incubation with 
a rhodamine labeled secondary antibody, the slides were 
counterstained with Dapi (Roche).
In vitro invasion assay
Mouse neuroblastoma cells positive or negative for 
Fzd6 were separated by FACS sorting and plated on the 
top well of invasion chambers in triplicate. The number 
of cells invading the bottom chamber was scored after 
staining with crystal violet.
Quantitative PCR
Quantitative real-time PCR was performed using 
Taq-Man master mix (Applied Byosistems) and a 7900HT 
Fast Real-Time PCR (Applied Biosystems). cDNAs were 
Figure 5: RNAi downregulation of Fzd6 inhibits neurospheres formation and expression of Wnt target genes. A) Fzd6 
positive R6-2 cells were separated by FACS sorting, transfected with scrambled (indicated by CTRL) or Fzd6 siRNA oligonucleotides and 
plated in neurospheres forming medium at the indicated concentrations. Statistical significance was assessed by two-sided T-test (n=3).   
B) Neurospheres obtained after transfection of R6-2 cells with scrambled or Fzd6 siRNA oligonucleotides were collected and subjected to 
analysis of gene expression by Real-time PCR. Gene expression levels observed in scrambled siRNA transfected cells were arbitrarily set to 
1 and compared to expression levels in Fzd6 siRNA transfected counterparts. Statistically significant differences obtained in 3 independent 
transfections are indicated. Oncotarget 2011; 2:  976 - 983 982 www.impactjournals.com/oncotarget
amplified using murine TaqMan Gene Expression Assays 
for the following genes: Oct-4 (Mm03053917_g1), 
Notch1 (Mm01326752_g1) , c-myc (Mm00487804_m1), 
Th (Mm00447549_g1), CD44 (Mm01277160_m1), 
Frizzled 6 (Mm00433383_m1), CcD1 (Mm03053889_
s1), Sox1 (Mm01209749_s1), Sox2 (Mm03053810_s1), 
Dhh (Mm03053542_s1), Twist (Mm00442036_m1), 
HPRT1 (Mm01545399_m1). The human TaqMan gene 
expression assays were: Myc (Hs00905030_m1), Notch1 
(Hs0162014_m1), Twist1 (Hs00361186_m1), CCND1 
(Hs00765553_m1),  Fzd6  (Hs00171574_m1),  GAPDH 
(Hs99999905_m1).
ACKNOWLEDGMENTS
This work was supported by the Wellcome Trust, 
the  RICC  cancer  fund,  SPARKS  (to  AS),  the  Italian 
Association  for  Cancer  Research  (MFAG  to  FP  and 
IG-5505 to MP), Regione Liguria (Progetto di Ricerca 
Sanitaria Regionale 2009 to VP) and the Italian Ministry 
of Health (to MP and VP).
REFERENCES
1.  Brodeur GM. Neuroblastoma: biological insights into a 
clinical enigma. Nat Rev Cancer. 2003; 3:203-216.
2.  Barembaum M, Bronner-Fraser M. Early steps in neural 
Figure 6: Fzd6 expression is associated with aggressive growth in vivo. A) Orthotopic transplantation of Fzd6 positive or 
negative cells into immunodeficient mice. Upper graph, bars indicate average tumours weights and Error bars indicate standard deviations. 
Statistical significance was verified by a two-sided Student T test (p=0.042). Neuroblastoma cells infiltrating the bone marrow of mice 
was assessed by flow cytometry (FACS) after incubation with an anti-GD2 mAb (bottom graph). Error bars indicate standard deviations 
and the statistical significance was verified by a two-sided Student T test (p=0.024). B) Immunofluorescence analysis of tumor sections 
from orthotopically implanted neuroblastomas showing increased expression of the indicated markers in Fzd6 positive versus negative 
tumors. Bar = 100μm (SMA, KI67, Notch1) or 10μm (Twist1). Quantitative assessment is shown in supplementary figure 2. C) Xenograft 
transplantation of SHSY5Y cells. 1x106 cells were injected in the flanks of immunodeficient SCID mice and tumor volumes were recorded 
at the indicated times. Regression lines represent average rates of growth. The P value refers to the difference in regression coefficients 
(Fzd6 positive R= 0.903, Fzd6 negative R= 0.658; p=0.037). D) Gene expression analysis in Fzd6 positive and negative SHSY5Y cells was 
conducted. Error bars indicate standard deviations of triplicate wells.Oncotarget 2011; 2:  976 - 983 983 www.impactjournals.com/oncotarget
crest specification. Semin Cell Dev Biol. 2005; 16:642-646.
3.  Burstyn-Cohen T, Stanleigh J, Sela-Donenfeld D, Kalcheim 
C. Canonical Wnt activity regulates trunk neural crest 
delamination linking BMP/noggin signaling with G1/S 
transition. Development. 2004; 131:5327-5339.
4.  Lyuksyutova AI, Lu CC, Milanesio N, King LA, Guo N, 
Wang Y, Nathans J, Tessier-Lavigne M, Zou Y. Anterior-
posterior guidance of commissural axons by Wnt-frizzled 
signaling. Science. 2003; 302:1984-1988.
5.  Reya T, Clevers H. Wnt signalling in stem cells and cancer. 
Nature. 2005; 434:843-850.
6.  Kuriyama S, Mayor R. Molecular analysis of neural crest 
migration. Philos Trans R Soc Lond B Biol Sci. 2008; 
363:1349-1362.
7.  Summerhurst K, Stark M, Sharpe J, Davidson D, Murphy 
P. 3D representation of Wnt and Frizzled gene expression 
patterns in the mouse embryo at embryonic day 11.5 (Ts19). 
Gene Expr Patterns. 2008; 8:331-348.
8.  Fischer T, Guimera J, Wurst W, Prakash N. Distinct but 
redundant expression of the Frizzled Wnt receptor genes 
at signaling centers of the developing mouse brain. 
Neuroscience. 2007; 147:693-711.
9.  Guo N, Hawkins C, Nathans J. Frizzled6 controls hair 
patterning in mice. Proceedings of the National Academy of 
Sciences of the United States of America. 2004; 101:9277-
9281.
10.  Stuebner S, Faus-Kessler T, Fischer T, Wurst W, Prakash 
N. Fzd3 and Fzd6 deficiency results in a severe midbrain 
morphogenesis defect. Dev Dyn. 2010; 239:246-260.
11.  Wang Y, Guo N, Nathans J. The role of Frizzled3 and 
Frizzled6 in neural tube closure and in the planar polarity 
of inner-ear sensory hair cells. J Neurosci. 2006; 26:2147-
2156.
12.  Wu QL, Zierold C, Ranheim EA. Dysregulation of Frizzled 
6 is a critical component of B-cell leukemogenesis in a 
mouse model of chronic lymphocytic leukemia. Blood. 
2009; 113:3031-3039.
13.  Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, 
Rich JN. Hypoxia inducible factors in cancer stem cells. Br 
J Cancer. 2010; 102:789-795.
14.  Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska 
I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty 
MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala 
A. Clusterin, a haploinsufficient tumor suppressor gene in 
neuroblastomas. J Natl Cancer Inst. 2009; 101:663-677.
15.  Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, 
Morozova  O,  Blakely  KM,  Rotenberg  SA,  Hansford 
LM, Miller FD, Yeger H, Irwin MS, Moffat J, Marra 
MA, Baruchel S, Wrana JL et al. Selective targeting of 
neuroblastoma tumour-initiating cells by compounds 
identified  in  stem  cell-based  small  molecule  screens. 
EMBO molecular medicine. 2010; 2:371-384.
16.  Heinonen  KM,  Vanegas  JR,  Lew  D,  Krosl  J,  Perreault 
C. Wnt4 enhances murine hematopoietic progenitor cell 
expansion through a planar cell polarity-like pathway. PloS 
one. 2011; 6:e19279.
17.  Pezzolo A, Parodi F, Marimpietri D, Raffaghello L, Cocco 
C, Pistorio A, Mosconi M, Gambini C, Cilli M, Deaglio S, 
Malavasi F, Pistoia V. Oct-4+/Tenascin C+ neuroblastoma 
cells serve as progenitors of tumor-derived endothelial 
cells. Cell Res. 2011; 21:1470-1486.
18.  Wagner W, Ansorge A, Wirkner U, Eckstein V, Schwager 
C, Blake J, Miesala K, Selig J, Saffrich R, Ansorge W, Ho 
AD. Molecular evidence for stem cell function of the slow-
dividing fraction among human hematopoietic progenitor 
cells by genome-wide analysis. Blood. 2004; 104:675-686.
19.  Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund 
J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro 
S,  Cammenga  J,  Fredlund  E,  Kaplan  DR,  Pahlman  S. 
HIF-2alpha maintains an undifferentiated state in neural 
crest-like human neuroblastoma tumor-initiating cells. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2009; 106:16805-16810.
20.  Hansford LM, McKee AE, Zhang L, George RE, Gerstle 
JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller 
FD, Irwin MS, Thiele CJ, Kaplan DR. Neuroblastoma cells 
isolated from bone marrow metastases contain a naturally 
enriched tumor-initiating cell. Cancer Res. 2007; 67:11234-
11243.
21.  Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim 
J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. Neuroblastoma 
cell lines contain pluripotent tumor initiating cells that are 
susceptible to a targeted oncolytic virus. PloS one. 2009; 
4:e4235.